137 related articles for article (PubMed ID: 35627717)
1. Efficacy of Clinical Guidelines in Identifying All Japanese Patients with Hereditary Breast and Ovarian Cancer.
Haneda E; Sato A; Suganuma N; Sebata Y; Okamoto S; Toda S; Kohagura K; Matsubara Y; Sugawara Y; Yamanaka T; Yamashita T; Shimizu S; Narimatsu H
Int J Environ Res Public Health; 2022 May; 19(10):. PubMed ID: 35627717
[TBL] [Abstract][Full Text] [Related]
2. BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?
Alemar B; Gregório C; Herzog J; Matzenbacher Bittar C; Brinckmann Oliveira Netto C; Artigalas O; Schwartz IVD; Coffa J; Alves Camey S; Weitzel J; Ashton-Prolla P
PLoS One; 2017; 12(11):e0187630. PubMed ID: 29161300
[TBL] [Abstract][Full Text] [Related]
3. Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.
Demir S; Tozkir H; Gurkan H; Atli EI; Yalcintepe S; Atli E; Sezer YA; Eker D; Tuncbilek N; Tastekin E; Ozen Y; Cicin I
J BUON; 2020; 25(3):1337-1347. PubMed ID: 32862574
[TBL] [Abstract][Full Text] [Related]
4. Risk-reducing mastectomy for women with hereditary breast and ovarian cancer (HBOC): analytical results of data from the Japanese Organization of HBOC.
Ohsumi S; Nakamura S; Miyata H; Watanabe C; Den H; Arai M
Jpn J Clin Oncol; 2022 Nov; 52(11):1265-1269. PubMed ID: 35905458
[TBL] [Abstract][Full Text] [Related]
5. [Present status and tasks for genetic testing and risk-reducing surgery in patients with hereditary breast and ovarian cancer].
Arai M; Taki K; Iwase H; Takizawa K; Nishimura S; Iwase T
Gan To Kagaku Ryoho; 2012 Apr; 39(4):525-31. PubMed ID: 22504676
[TBL] [Abstract][Full Text] [Related]
6. [Current clinical issues and recent trends in hereditary breast and ovarian cancer in Japan-genetic testing for HBOC and risk-reducing surgery].
Arai M; Iwase T; Takazawa Y; Takeshima N
Gan To Kagaku Ryoho; 2014 Nov; 41(11):1333-9. PubMed ID: 25434434
[TBL] [Abstract][Full Text] [Related]
7. NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024.
Daly MB; Pal T; Maxwell KN; Churpek J; Kohlmann W; AlHilli Z; Arun B; Buys SS; Cheng H; Domchek SM; Friedman S; Giri V; Goggins M; Hagemann A; Hendrix A; Hutton ML; Karlan BY; Kassem N; Khan S; Khoury K; Kurian AW; Laronga C; Mak JS; Mansour J; McDonnell K; Menendez CS; Merajver SD; Norquist BS; Offit K; Rash D; Reiser G; Senter-Jamieson L; Shannon KM; Visvanathan K; Welborn J; Wick MJ; Wood M; Yurgelun MB; Dwyer MA; Darlow SD
J Natl Compr Canc Netw; 2023 Oct; 21(10):1000-1010. PubMed ID: 37856201
[TBL] [Abstract][Full Text] [Related]
8. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
9. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing.
Sharma P; Klemp JR; Kimler BF; Mahnken JD; Geier LJ; Khan QJ; Elia M; Connor CS; McGinness MK; Mammen JM; Wagner JL; Ward C; Ranallo L; Knight CJ; Stecklein SR; Jensen RA; Fabian CJ; Godwin AK
Breast Cancer Res Treat; 2014 Jun; 145(3):707-14. PubMed ID: 24807107
[TBL] [Abstract][Full Text] [Related]
10. Overview of hereditary breast and ovarian cancer (HBOC) guidelines across Europe.
Marmolejo DH; Wong MYZ; Bajalica-Lagercrantz S; Tischkowitz M; Balmaña J;
Eur J Med Genet; 2021 Dec; 64(12):104350. PubMed ID: 34606975
[TBL] [Abstract][Full Text] [Related]
11. Identification of germline pathogenic variants in DNA damage repair genes by a next-generation sequencing multigene panel in BRCAX patients.
Rodríguez-Balada M; Roig B; Melé M; Albacar C; Serrano S; Salvat M; Querol M; Borràs J; Martorell L; Gumà J
Clin Biochem; 2020 Feb; 76():17-23. PubMed ID: 31786208
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of family history in individuals with heterozygous BRCA pathogenic variants diagnosed with breast or ovarian cancer in a single center in Italy.
Negri S; De Ponti E; Sina FP; Sala E; Dell'Oro C; Roversi G; Lazzarin S; Delle Marchette M; Inzoli A; Toso C; Fumagalli S; Campanella M; Kotsopoulos J; Fruscio R
Mol Genet Genomic Med; 2022 Dec; 10(12):e2071. PubMed ID: 36307994
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of germline pathogenic
Morgan RD; Burghel GJ; Flaum N; Bulman M; Clamp AR; Hasan J; Mitchell CL; Schlecht H; Woodward ER; Lallo FI; Crosbie EJ; Edmondson RJ; Wallace AJ; Jayson GC; Evans DGR
J Med Genet; 2019 May; 56(5):301-307. PubMed ID: 30683677
[TBL] [Abstract][Full Text] [Related]
14. Optimization of prediction methods for risk assessment of pathogenic germline variants in the Japanese population.
Senda N; Kawaguchi-Sakita N; Kawashima M; Inagaki-Kawata Y; Yoshida K; Takada M; Kataoka M; Torii M; Nishimura T; Kawaguchi K; Suzuki E; Kataoka Y; Matsumoto Y; Yoshibayashi H; Yamagami K; Tsuyuki S; Takahara S; Yamauchi A; Shinkura N; Kato H; Moriguchi Y; Okamura R; Kan N; Suwa H; Sakata S; Mashima S; Yotsumoto F; Tachibana T; Tanaka M; Togashi K; Haga H; Yamada T; Kosugi S; Inamoto T; Sugimoto M; Ogawa S; Toi M
Cancer Sci; 2021 Aug; 112(8):3338-3348. PubMed ID: 34036661
[TBL] [Abstract][Full Text] [Related]
15. Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients.
Crawford B; Adams SB; Sittler T; van den Akker J; Chan S; Leitner O; Ryan L; Gil E; van 't Veer L
Breast Cancer Res Treat; 2017 Jun; 163(2):383-390. PubMed ID: 28281021
[TBL] [Abstract][Full Text] [Related]
16. Hereditary cancer-associated mutations in women diagnosed with two primary cancers: an opportunity to identify hereditary cancer syndromes after the first cancer diagnosis.
Saam J; Moyes K; Landon M; Williams K; Kaldate RR; Arnell C; Wenstrup R
Oncology; 2015; 88(4):226-33. PubMed ID: 25503195
[TBL] [Abstract][Full Text] [Related]
17. Consolidated BRCA1/2 Variant Interpretation by MH BRCA Correlates with Predicted PARP Inhibitor Efficacy Association by MH Guide.
Hirotsu Y; Schmidt-Edelkraut U; Nakagomi H; Sakamoto I; Hartenfeller M; Narang R; Soldatos TG; Kaduthanam S; Wang X; Hettich S; Brock S; Jackson DB; Omata M
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486089
[No Abstract] [Full Text] [Related]
18. Rapid screening test of most frequent BRCA1/BRCA2 pathogenic variants in the NGS era.
Zidekova D; Waczulikova I; Dolesova L; Vavrova L; Hamidova O; Lohajova Behulova R; Konecny M
Neoplasma; 2018; 65(2):309-315. PubMed ID: 29534594
[TBL] [Abstract][Full Text] [Related]
19. The implications of BRCA loss of heterozygosity (LOH) and deficient mismatch repair gene (dMMR) expression in the breast cancer of a patient with both inherited breast and ovarian cancer syndrome (BRCA2) and Lynch syndrome (MLH1).
Sorscher S; Ansley K; Delaney SD; Ramkissoon S
Breast Cancer Res Treat; 2020 Apr; 180(2):511-514. PubMed ID: 32040686
[TBL] [Abstract][Full Text] [Related]
20. Identifying Women at Risk for Hereditary Breast and Ovarian Cancer Syndrome Utilizing Breast Care Nurse Navigation at Mammography and Imaging Centers.
Appel SJ; Cleiment RJ
J Natl Black Nurses Assoc; 2015 Dec; 26(2):17-26. PubMed ID: 27045154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]